[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability
Authors:
- Tatiana Nikolaevna LazutinaTLTatiana Nikolaevna Lazutina
- Aleksandr Igorevich KhalimonAKAleksandr Igorevich Khalimon
- Soslan Rolanovich UrtaevSUSoslan Rolanovich Urtaev
- Malika Maratovna KhodzhibekovaMKMalika Maratovna Khodzhibekova
- Daria Yurevna KhodakovaDKDaria Yurevna Khodakova
- Gulnara Faridovna KhamadeevaGKGulnara Faridovna Khamadeeva
- Anastasia Igorevna NikiforukANAnastasia Igorevna Nikiforuk
- Irina Valentinovna PylovaIPIrina Valentinovna Pylova
- Andrey Dmitrievich KaprinAKAndrey Dmitrievich Kaprin
Open Access
- 10 April 2026
- journal article
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Abstract
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression in TNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment of TNBC patients. This prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT). A total of 229 lesions were identified using both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸F]PSMA-1007. [¹⁸F]FDG demonstrated higher uptake in TNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used. Despite detectable [¹⁸F]PSMA-1007 uptake in TNBC lesions, [¹⁸F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed in TNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.Keywords
This publication has 32 references indexed in Scilit:
- Annual Congress of the European Association of Nuclear Medicine, October 4–8, 2025 | Barcelona, SpainEANM Innovation, 2025
- Evaluation of prostate-specific membrane antigen expression in locally advanced or metastatic breast carcinoma with 68Ga-PSMA-11 positron-emission tomography/computed tomography imaging for potential theranosticsNuclear Medicine Communications, 2024
- The roles of 68Ga-PSMA PET/CT and 18F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findingsNuclear Medicine Communications, 2023
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2021
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialThe Lancet, 2021
- Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapyBreast Cancer Research and Treatment, 2018
- Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastasesClinical & Experimental Metastasis, 2017
- 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancersAPMIS, 2013
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007